GlycoPEGylated factor IX: A new step forward

Maria Elisa Mancuso

Research output: Contribution to journalArticlepeer-review


In this issue of Blood, Collins et al provide the results of a prospective, randomized, single-blind, phase 3 trial on the use of nonacog beta pegol, a new long-acting glycoPEGylated factor IX (FIX) molecule for the treatment and prevention of bleeding episodes in 74 patients with hemophilia B.

Original languageEnglish
Pages (from-to)3836-3837
Number of pages2
Issue number26
Publication statusPublished - Dec 18 2014

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)


Dive into the research topics of 'GlycoPEGylated factor IX: A new step forward'. Together they form a unique fingerprint.

Cite this